BioSpace News Archive

Dental Forceps Market: Growing numbers of dental surgeries is expected to drive the market

New designs and materials used for making dental forceps have expanded the armamentarium of dentists seeking better tools for teeth extraction procedures.

January 9, 2022
·
5 min read
Intraoperative Radiation Therapy Market: Breast Cancer Segment to Dominate Global Market

Intraoperative radiation therapy is a treatment for cancer wherein an ionizing radiation is administered to a small area of the body all at once during a surgery.

January 9, 2022
·
6 min read
Severe Combined Immunodeficiency Treatment Market: Availability of Drugs and Immune-related Treatments Are Anticipated to Drive the Global Market

Severe combined immunodeficiency is a group of rare disorders caused by mutation in different genes.

January 9, 2022
·
7 min read
Business

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

Exagen Inc., a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced the execution of a research collaboration and exclusive license agreement.

January 9, 2022
·
7 min read
Hansa Biopharma provides business update including certain key financials

Hansa Biopharma AB, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announces a business update for the fourth quarter 2021 and certain preliminary, unaudited key financials for its financial year 2021.

January 9, 2022
·
10 min read
Business

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.

January 9, 2022
·
8 min read
Business

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced preliminary unaudited financial and operational results for the fourth quarter and fiscal year 2021.

January 9, 2022
·
4 min read
Drug Development

BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis

BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc. announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.

January 9, 2022
·
11 min read
Business

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022

The Company expects to report total revenues of approximately $1,471.1 million, a decrease of compared to the prior year period, or in constant currency.

January 9, 2022
·
11 min read
BioCapital

Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results

Emergent BioSolutions Inc. announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021.

January 9, 2022
·
15 min read